Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment-Reference-Cited by-同舟云学术

Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment

Published:2024-01-31 Issue:3 Volume:27 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Sun Yixuan¹,Zhao Junfeng²,Du Jiachen³,Li Ying⁴,Ding Fangjie⁵,Zhao Wenbo¹

Affiliation:

1. Department of Hematology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, Jinan, Shandong 250021, P.R. China

2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China

3. Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong 250021, P.R. China

4. Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China

5. Department of Radiation Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, Shandong 250013, P.R. China

Publisher

Spandidos Publications

Reference32 articles.

1. Multiple myeloma epidemiology and survival: A unique malignancy;Kazandjian;Semin Oncol,2016

2. Multiple myeloma;Röllig;Lancet,2015

3. Multiple myeloma: Diagnosis and treatment;Rajkumar;Mayo Clin Proc,2016

4. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma;Attal;N Engl J Med,2017

5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): A randomised, open-label, phase 3 study;Moreau;Lancet,2019